Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable monitoring of a patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solution is designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion.The company's shares are listed on Nasdaq First North (ticker SEZI).
Copyright 2016, a2z, Inc. All rights reserved.